RESTYLANE Vital approved in Europe
May 27, 2004 03:22 ET
|
Q-Med
UPPSALA, Sweden, May 27, 2004 (PRIMEZONE) -- Q-Med's new product, RESTYLANE Vital, has obtained CE certification for the indication for hydration of the skin by injections. The approval of RESTYLANE...
Q-Med has received a payment of USD 19.4 million from Medicis
May 17, 2004 04:15 ET
|
Q-Med
UPPSALA, Sweden, May 17, 2004 (PRIMEZONE) -- Due to the fact that Medicis has met the sales criteria stipulated in the agreement, Q-Med has received a supplementary purchase sum of USD 19.4 million...
Annual General Meeting Of Q-Med Ab (Publ)
May 07, 2004 02:44 ET
|
Q-Med
UPPSALA, Sweden, May 07, 2004 (PRIMEZONE) --Q-MED AB (publ):
-- Total dividend of SEK 13 per share.
-- Mikael Kamras elected as new member of the Board.
The Annual General Meeting of Q-Med AB...
Q-Med: Interim Report January -- March 2004
May 06, 2004 10:06 ET
|
Q-Med
UPPSALA, Sweden, May 06, 2004 (PRIMEZONE) --
-- Turnover for the first quarter of 2004 amounted to SEK 179.7 (141.3) million, which is an increase of 27 percent.
-- Operating income amounted to...
Annual General Meeting of Q-Med AB (publ)
April 02, 2004 01:39 ET
|
Q-Med
UPPSALA, Sweden, April 02, 2004 (PRIMEZONE) -- The Board of Directors in Q-Med AB (publ) has of today announced a notice to attend the Annual General Meeting, which will be held on Thursday May 6,...
Q-Med: RESTYLANE SubQ approved in Europe
March 29, 2004 08:04 ET
|
Q-Med
UPPSALA, Sweden, March 29, 2004 (PRIMEZONE) -- Q-Med's new product, RESTYLANE SubQ, has got a CE certification with the indication for subcutaneous tissue augmentation, recommended by Q-Med to be...
DUROLANE approved in Europe for the treatment of osteoarthritis of the hip joint.
March 09, 2004 09:39 ET
|
Q-Med
UPPSALA, Sweden, March 9, 2004 (PRIMEZONE) -- Q-Med's product DUROLANE has obtained a CE-mark for the treatment of osteoarthritis of the hip joint, which means that it for this indication as well,...
Q-Med Report on operations 2003
February 12, 2004 05:41 ET
|
Q-Med
UPPSALA, Sweden, Feb. 12, 2004 (PRIMEZONE) -- Q-Med:
-Turnover during 2003 amounted to SEK 607.4 (517.8) million, of which SEK 179.6 (148.3) million was during the fourth quarter.
- Operating...
Q-Med Licenses Oxalate Control Project from the Subsidiary Company Ixion
January 26, 2004 12:12 ET
|
Q-Med
UPPSALA, Sweden, Jan. 26, 2004 (PRIMEZONE) -- Ixion Biotechnology Inc., an affiliated company of Q-Med, has decided to license out its oxalate technology to Q-Med.
The agreement means that Q-Med...
Q-Med starts study within new medical area
January 14, 2004 07:04 ET
|
Q-Med
UPPSALA, Sweden, Jan. 14, 2004 (PRIMEZONE) -- Q-Med has obtained approval from the Swedish Medical Products Agency to begin a study on patients with GastroEsophageal Reflux Disease, GERD.
GERD...